CN110143935A - 一种2,5-二取代呋喃衍生物的制备方法 - Google Patents
一种2,5-二取代呋喃衍生物的制备方法 Download PDFInfo
- Publication number
- CN110143935A CN110143935A CN201910478911.8A CN201910478911A CN110143935A CN 110143935 A CN110143935 A CN 110143935A CN 201910478911 A CN201910478911 A CN 201910478911A CN 110143935 A CN110143935 A CN 110143935A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tert
- alkali
- diketone
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种2,5‑二取代呋喃衍生物的制备方法,本发明在切断一根碳碳键的同时构建一根新的碳碳键,最终环化为2,5‑二取代呋喃衍生物,具有良好的区域选择性。本发明的方法所用原料易得,收率高,反应条件温和,反应时间短,底物范围广,反应专一性强,后处理简便且绿色。
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种2,5-二取代呋喃衍生物的制备方法。
背景技术
2,5-二取代呋喃是基本的有机结构单元之一,同时它也广泛存在于天然产物中,也是工业有机合成中的重要中间体,广泛应用于医药、食品香料、农药等诸多领域。比如,具有显著抗菌活性的呋喃唑酮(furazolidonum)对肠炎、菌痢和结肠癌等多种肠道感染疾病均有明显的药物活性,呋喃环单酰基脲衍生物具有明显的抑制昆虫几丁质形成的活性,并且对环境友好,广泛应用于农业中。因此,2,5-二取代呋喃的合成是有机化学的重要内容之一,其中,现有技术中的2,5-二取代呋喃的合成方法在区域和立体选择性上的效果仍然不尽如人意。
发明内容
本发明的目的在于提供一种2,5-二取代呋喃衍生物的制备方法。
本发明的技术方案如下:
一种2,5-二取代呋喃衍生物的制备方法,包括如下步骤:
(1)向反应容器中加入碱、1,3-二芳基1,3-二酮、钌催化剂、添加剂、硫叶立德和有机溶剂,空气气氛下100-120℃反应12-24h;该硫叶立德的结构式为该钌催化剂为对甲基异丙基苯二氯化钌(II)二聚体;该添加剂为2,4,6-三甲基苯甲酸;
(2)将步骤(1)所得的物料经乙酸乙酯稀释后,再经水洗,分离得有机相;
(3)将步骤(2)所得的有机相经干燥、过滤、浓缩和柱层析色谱或薄层色谱,得到所述2,5-二取代呋喃衍生物;其结构式为
其中R为氢、烷基、烷氧基、三氟甲基、卤素或杂环基。
在本发明的一个优选实施方案中,所述碱为氢氧化钠、氢氧化钾、叔丁醇锂、叔丁醇钠、叔丁醇钾、甲醇钠、乙醇钠、碳酸钠、碳酸钾、磷酸钾、磷酸二氢钾、碳酸铯。
进一步优选的,所述碱为叔丁醇锂。
在本发明的一个优选实施方案中,所述有机溶剂为二甲基亚砜、N,N-二甲基甲酰胺、N-甲基-2-吡咯烷酮、1,2-二氯乙烷、甲苯、1,4-二氧六环、四氢呋喃、乙二醇二甲醚或甲基叔丁基醚。
进一步优选的,所述有机溶剂为甲苯。
在本发明的一个优选实施方案中,所述卤素为氟、氯或溴。
在本发明的一个优选实施方案中,所述碱为叔丁醇锂,所述有机溶剂为甲苯,所述卤素为氟、氯或溴。
在本发明的一个优选实施方案中,所述反应的温度为120℃,时间为24h。
在本发明的一个优选实施方案中,所述1,3-二芳基1,3-二酮、硫叶立德、钌催化剂、添加剂和碱的摩尔比为1-2∶1-0.1∶1-2∶1-2,且每摩尔1,3-二芳基1,3-二酮对应的所述有机溶剂为1-3L。
进一步优选的,所述1,3-二芳基1,3-二酮、硫叶立德、钌催化剂、添加剂以及碱的摩尔比为1∶2∶0.05∶1.5∶1.5,且每摩尔1,3-二芳基1,3-二酮对应的所述有机溶剂为1-2L。
本发明的有益效果是:
1、本发明在切断一根碳碳键的同时构建一根新的碳碳键,最终环化为2,5-二取代呋喃衍生物,具有良好的区域选择性。
2、本发明的方法所用原料易得,收率高,反应条件温和,反应时间短,底物范围广,反应专一性强,后处理简便且绿色。
具体实施方式
以下通过具体实施方式对本发明的技术方案进行进一步的说明和描述。
实施例1
2-苯基-5-邻甲苯基呋喃的制备
将叔丁醇锂0.15mmol、1,3-二苯基-1,3-丙二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(邻甲苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到16.9mg的目标产物,收率为73%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.81(d,J=7.8Hz,1H),7.78-7.75(m,2H),7.42(t,J=7.8Hz,2H),7.33-7.25(m,3H),7.27-7.20(m,1H),6.79(d,J=3.5Hz,1H),6.66(d,J=3.4Hz,1H),2.59(s,3H);13C NMR(126MHz,Chloroform-d)6153.1,153.0,134.4,131.3,130.8,130.0,128.7,127.4,127.3,126.8,126.0,123.7,110.6,106.9,22.1.
实施例2
2-(3-氯苯基)-5-苯基呋喃的制备
将叔丁醇锂0.15mmol、1,3-二苯基-1,3-丙二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、1-(3-氯苯基)-2-(二甲基(氧代)-λ6硫烷基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到11.9mg的目标产物,收率为47%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.77-7.74(m,2H),7.73(t,J=1.9Hz,1H),7.61(m,1H),7.45-7.40(m,2H),7.35-7.28(m,2H),7.25-7.22(m,1H),6.78-6.74(m,2H);13C NMR(126MHz,Chloroform-d)δ153.9,151.8,134.7,132.4,130.4,130.0,128.7,127.6,127.1,123.8,123.6,121.7,108.3,107.3.
实施例3
2-(4-甲氧基苯基)-5-苯基呋喃的制备
将叔丁醇锂0.15mmol、1,3-二苯基-1,3-丙二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(4-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到11.8mg的目标产物,收率为47%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.75-7.72(m,2H),7.71-7.67(m,2H),7.40(t,J=7.8Hz,2H),7.30-7.22(m,1H),6.97-6.94(m,2H),6.72(d,J=3.4Hz,1H),6.61(d,J=3.4Hz,1H),3.85(s,3H);13C NMR(126MHz,Chloroform-d)δ159.0,153.4,152.6,130.9,128.6,127.1,125.2,123.9,123.5,114.1,107.2,105.6,55.3.
实施例4
2-(4-氯苯基)-5-苯基呋喃的制备
将叔丁醇锂0.15mmol、1,3-二苯基-1,3-丙二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、1-(4-氯苯基)-2-(二甲基(氧代)-λ6硫烷基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到12.9mg的目标产物,收率为51%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.79-7.71(m,2H),7.70-7.62(m,2H),7.42(t,J=7.7Hz,2H),7.37(d,J=8.6Hz,2H),7.29(t,J=7.4Hz,1H),6.74(q,J=3.5Hz,2H);13C NMR(126MHz,Chloroform-d)δ153.6,152.2,132.9,130.5,129.2,128.9(d,J=5.4Hz),128.7,127.5,124.9(d,J=6.5Hz),123.7,107.7,107.3.
实施例5
2-([1,1′-联苯]-4-基)-5-苯基呋喃的制备
将叔丁醇锂0.15mmol、1,3-二苯基-1,3-丙二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、1-([1,1′-联苯]-4-基)-2-(二甲基(氧代)-λ6硫烷基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到17.6mg的目标产物,收率为60%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.86-7.82(m,2H),7.81-7.75(m,2H),7.70-7.62(m,4H),7.51-7.41(m,4H),7.37(t,J=7.4Hz,1H),7.29(t,J=7.4Hz,1H),6.81-6.76(m,2H);13C NMR(126MHz,Chloroform-d)δ153.4,153.1,140.6,139.9,130.7,129.7,128.8,128.7,127.4,126.9,124.1,123.7,107.4,107.3.
实施例6
2-苯基-5-(噻吩-2-基)呋喃的制备
将叔丁醇锂0.15mmol、1,3-二苯基-1,3-丙二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(噻吩-2-基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到12.5mg的目标产物,收率为55%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.76-7.69(m,2H),7.41(t,J=7.8Hz,2H),7.34-7.31(m,1H),7.30-7.26(m,1H),7.26-7.23(m,1H),7.10-7.04(m,1H),6.71(d,J=3.4Hz,1H),6.59(d,J=3.5Hz,1H).13C NMR(126MHz,Chloroform-d)δ152.9,148.9,133.7,130.5,128.7,127.7,127.4,124.2,124.1,123.7,122.7,122.5,107.2,107.1.
实施例7
2-(2-甲氧基苯基)-5-(邻甲苯基)呋喃的制备
将叔丁醇锂0.15mmol、1,3-二邻甲苯基丙-1,3-二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(2-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到13.9的目标产物,收率为53%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.97-7.94(m,1H),7.83-7.77(m,1H),7.29-7.24(m,3H),7.24-7.18(m,1H),7.06(d,J=3.5Hz,1H),7.04(dd,J=7.5,1.1Hz,1H),6.98(d,J=8.2Hz,1H),6.66(d,J=3.5Hz,1H),3.96(s,3H),2.58(s,3H);13C NMR(126MHz,Chloroform-d)δ155.5,152.0,149.4,134.4,131.2,130.2,128.0,127.3,126.9,126.0,125.8,120.8,119.8,111.9,110.9,110.8,55.4,22.1.
实施例8
2-(2-甲氧基苯基)-5-(间甲苯基)呋喃的制备
将叔丁醇锂0.15mmol、1,3-二间甲苯基丙-1,3-二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(2-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到19.8mg的目标产物,收率为63%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ8.02-7.97(m,1H),7.56(d,J=11.4Hz,2H),7.28(t,J=7.6Hz,1H),7.26-7.21(m,1H),7.10-7.00(m,3H),6.96(d,J=8.3Hz,1H),6.75-6.73(m,1H),3.94(s,3H),2.40(s,3H).13C NMR(126MHz,Chloroform-d)δ155.4,152.4,149.6,138.2,130.8,128.6,128.0,127.9,125.8,124.3,121.0,120.7,119.8,112.2,111.0,107.3,55.3,21.5.
实施例9
2-(3-氯苯基)-5-(2-甲氧基苯基)呋喃的制备
将叔丁醇锂0.15mmol、1,3-双(3-氯苯基)丙烷-1,3-二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(2-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到20mg的目标产物,收率为70%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.99-7.95(m,1H),7.72(t,J=1.8Hz,1H),7.60(d,J=7.8Hz,1H),7.31(t,J=7.9Hz,1H),7.28-7.23(m,1H),7.23-7.19(m,1H),7.06(t,J=7.5Hz,1H),7.03(d,J=3.5Hz,1H),6.97(d,J=8.0Hz,1H),6.77(d,J=3.4Hz,1H),3.95(s,3H);13C NMR(126MHz,Chloroform-d)δ155.6,150.7,150.4,134.7,132.5,129.9,128.3,127.0,125.9,123.6,121.7,120.8,119.4,112.3,111.0,108.5,55.4.
实施例10
2-(2-甲氧基苯基)-5-(4-甲氧基苯基)呋喃的制备
将叔丁醇锂0.15mmol、1,3-双(4-甲氧基苯基)丙烷-1,3-二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(2-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到13.5mg的目标产物,收率为48%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.96(dd,J=7.8,1.8Hz,1H),7.72-7.65(m,2H),7.25-7.21(m,1H),7.06-7.02(m,1H),7.01(d,J=3.4Hz,1H),6.97-6.92(m,3H),6.62(d,J=3.4Hz,1H),3.94(s,3H),3.83(s,3H);13C NMR(126MHz,Chloroform-d)δ158.9,155.3,152.3,149.1,127.7,125.6,125.2,124.0,120.7,119.9,114.1,112.2,110.9,105.8,55.3(d,J=3.4Hz).
实施例11
2-(4-氯苯基)-5-(2-甲氧基苯基)呋喃的制备
将叔丁醇锂0.15mmol、1,3-双(4-氯苯基)丙烷-1,3-二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(2-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到17mg的目标产物,收率为60%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.98-7.92(m,1H),7.69-7.64(m,2H),7.37-7.33(m,2H),7.27-7.23(m,1H),7.07-7.03(m,1H),7.02(d,J=3.4Hz,1H),6.97(d,J=8.2Hz,1H),6.74(d,J=3.5Hz,1H),3.95(s,3H);13C NMR(126MHz,Chloroform-d)δ155.5,151.1,150.1,132.7,129.4,128.8,128.2,125.8,124.9,120.7,119.5,112.3,111.0,107.8,55.4.
实施例12
5-(2-甲氧基苯基)-2,2′-二呋喃的制备
将叔丁醇锂0.15mmol、1,3-二(呋喃-2-基)丙烷-1,3-二酮0.1mmol,对甲基异丙基苯二氯化钌(II)二聚体0.005mmol、2,4,6-三甲基苯甲酸0.15mmol、2-(二甲基(氧代)-λ6硫烷基)-1-(2-甲氧基苯基)乙-1-酮0.2mmol、和甲苯2mL加入到15mL的反应管中,置于120℃的油浴中,空气气氛下反应24h;冷却至室温,反应液用乙酸乙酯稀释,水洗三次,有机相用无水Na2SO4干燥,过滤,浓缩,薄层色谱纯化得到9.5mg的目标产物,收率为40%。该目标产物的核磁和高分辨质谱表征如下:1H NMR(500MHz,Chloroform-d)δ7.97-7.90(m,1H),7.43(d,J=2.0Hz,1H),7.28-7.22(m,1H),7.07-7.02(m,1H),7.01(d,J=3.3Hz,1H),6.96(d,J=8.4Hz,1H),6.68-6.61(m,2H),6.51-6.45(m,1H),3.94(s,3H);13C NMR(126MHz,Chloroform-d)δ155.4,149.5,146.8,145.0,141.7,128.1,125.8,120.7,119.5,111.8,111.4,110.9,107.4,105.0,55.4.
以上所述,仅为本发明的较佳实施例而已,故不能依此限定本发明实施的范围,即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。
Claims (10)
1.一种2,5-二取代呋喃衍生物的制备方法,其特征在于:包括如下步骤:
(1)向反应容器中加入碱、1,3-二芳基1,3-二酮、钌催化剂、添加剂、硫叶立德和有机溶剂,空气气氛下100-120℃反应12-24h;该硫叶立德的结构式为该钌催化剂为对甲基异丙基苯二氯化钌(II)二聚体;该添加剂为2,4,6-三甲基苯甲酸;
(2)将步骤(1)所得的物料经乙酸乙酯稀释后,再经水洗,分离得有机相;
(3)将步骤(2)所得的有机相经干燥、过滤、浓缩和柱层析色谱或薄层色谱,得到所述2,5-二取代呋喃衍生物;其结构式为
其中R为氢、烷基、烷氧基、三氟甲基、卤素或杂环基。
2.如权利要求1所述的制备方法,其特征在于:所述碱为氢氧化钠、氢氧化钾、叔丁醇锂、叔丁醇钠、叔丁醇钾、甲醇钠、乙醇钠、碳酸钠、碳酸钾、磷酸钾、磷酸二氢钾、碳酸铯。
3.如权利要求2所述的制备方法,其特征在于:所述碱为叔丁醇锂。
4.如权利要求1所述的制备方法,其特征在于:所述有机溶剂为二甲基亚砜、N,N-二甲基甲酰胺、N-甲基-2-吡咯烷酮、1,2-二氯乙烷、甲苯、1,4-二氧六环、四氢呋喃、乙二醇二甲醚或甲基叔丁基醚。
5.如权利要求4所述的制备方法,其特征在于:所述有机溶剂为甲苯。
6.如权利要求1所述的制备方法,其特征在于:所述卤素为氟、氯或溴。
7.如权利要求1所述的制备方法,其特征在于:所述碱为叔丁醇锂,所述有机溶剂为甲苯,所述卤素为氟、氯或溴。
8.如权利要求1所述的制备方法,其特征在于:所述反应的温度为120℃,时间为24h。
9.如权利要求1所述的制备方法,其特征在于:所述1,3-二芳基1,3-二酮、硫叶立德、钌催化剂、添加剂和碱的摩尔比为1-2∶1-0.1∶1-2∶1-2,且每摩尔1,3-二芳基1,3-二酮对应的所述有机溶剂为1-3L。
10.如权利要求9所述的制备方法,其特征在于:所述1,3-二芳基1,3-二酮、硫叶立德、钌催化剂、添加剂以及碱的摩尔比为1∶2∶0.05∶1.5∶1.5,且每摩尔1,3-二芳基1,3-二酮对应的所述有机溶剂为1-2L。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910478911.8A CN110143935B (zh) | 2019-06-03 | 2019-06-03 | 一种2,5-二取代呋喃衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910478911.8A CN110143935B (zh) | 2019-06-03 | 2019-06-03 | 一种2,5-二取代呋喃衍生物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110143935A true CN110143935A (zh) | 2019-08-20 |
CN110143935B CN110143935B (zh) | 2022-09-30 |
Family
ID=67590230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910478911.8A Active CN110143935B (zh) | 2019-06-03 | 2019-06-03 | 一种2,5-二取代呋喃衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110143935B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112142642A (zh) * | 2020-10-15 | 2020-12-29 | 华侨大学 | 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030100774A1 (en) * | 2001-10-05 | 2003-05-29 | Wyeth | Process for synthesis of 2-yl chroman derivatives |
US20040116404A1 (en) * | 2001-04-05 | 2004-06-17 | Pineiro Jose Luis Castro | Sulphones which modulate the action of gamma secretase |
WO2008080986A1 (en) * | 2006-12-28 | 2008-07-10 | Neuropharma, S.A. | Furan derivatives, method of synthesis and uses thereof |
US20080319074A1 (en) * | 2005-11-18 | 2008-12-25 | Mark Donald Chappell | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses |
US20090048213A1 (en) * | 2006-07-28 | 2009-02-19 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
CN102887808A (zh) * | 2012-10-26 | 2013-01-23 | 华东师范大学 | 一种多取代茚醇衍生物的制备方法 |
CN106565578A (zh) * | 2016-10-17 | 2017-04-19 | 华东师范大学 | 一种光学活性四氢吡咯衍生物及其合成方法和应用 |
US20180099987A1 (en) * | 2016-10-11 | 2018-04-12 | King Fahd University Of Petroleum And Minerals | Functionalized magnetic nanoparticle, a catalyst, a method for forming c-c bonds |
CN109762018A (zh) * | 2019-01-17 | 2019-05-17 | 大连理工大学 | 一种钌催化的磷氮烯化合物的制备方法 |
-
2019
- 2019-06-03 CN CN201910478911.8A patent/CN110143935B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116404A1 (en) * | 2001-04-05 | 2004-06-17 | Pineiro Jose Luis Castro | Sulphones which modulate the action of gamma secretase |
US20030100774A1 (en) * | 2001-10-05 | 2003-05-29 | Wyeth | Process for synthesis of 2-yl chroman derivatives |
US20080319074A1 (en) * | 2005-11-18 | 2008-12-25 | Mark Donald Chappell | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses |
US20090048213A1 (en) * | 2006-07-28 | 2009-02-19 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
WO2008080986A1 (en) * | 2006-12-28 | 2008-07-10 | Neuropharma, S.A. | Furan derivatives, method of synthesis and uses thereof |
CN102887808A (zh) * | 2012-10-26 | 2013-01-23 | 华东师范大学 | 一种多取代茚醇衍生物的制备方法 |
US20180099987A1 (en) * | 2016-10-11 | 2018-04-12 | King Fahd University Of Petroleum And Minerals | Functionalized magnetic nanoparticle, a catalyst, a method for forming c-c bonds |
CN106565578A (zh) * | 2016-10-17 | 2017-04-19 | 华东师范大学 | 一种光学活性四氢吡咯衍生物及其合成方法和应用 |
CN109762018A (zh) * | 2019-01-17 | 2019-05-17 | 大连理工大学 | 一种钌催化的磷氮烯化合物的制备方法 |
Non-Patent Citations (4)
Title |
---|
BEKIR ÇETINKAYA 等: "2-Imidazoline– and 1,4,5,6-tetrahydropyrimidine–ruthenium(II) complexes and catalytic synthesis of furan", 《JOURNAL OF ORGANOMETALLIC CHEMISTRY》 * |
WEIWEI LV,GUOLIN CHENG 等: "Palladium-Catalyzed Ortho-Silylation of Aryl Iodides with Concomitant Arylsilylation of Oxanorbornadiene: Accessing Functionalized (Z)-β-Substituted Vinylsilanes and Their Analogues", 《ORGANIC LETTERS》 * |
YUNXIANG WENG,GUOLIN CHENG 等: "Synthesis of 2-Aminopyridines via a Base-Promoted Cascade Reaction of N-Propargylic β-Enaminones with Formamides", 《THE JOURNAL OF ORGANIC CHEMISTRY》 * |
吴健 等: "3-亚甲基异苯并呋喃-1( 3H) -酮的合成", 《化学研究与应用》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112142642A (zh) * | 2020-10-15 | 2020-12-29 | 华侨大学 | 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110143935B (zh) | 2022-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6732744B2 (ja) | ルテニウム触媒作用によるアゾベンゾール類からのビフェニルアミン類の製造方法 | |
Liu et al. | Efficient 2-aryl benzothiazole formation from acetophenones, anilines, and elemental sulfur by iodine-catalyzed oxidative C (CO)-C (alkyl) bond cleavage | |
CN110128393A (zh) | 一种取代异香豆素衍生物的制备方法 | |
Reddy et al. | A [3+ 2]-annulation approach to tetrasubstituted furans from MBH-carbonates of acetylenic aldehydes via sequential substitution/cycloisomerization | |
CN105175328A (zh) | 一种利用芳香胺、芳香醛、酮合成喹啉衍生物的方法 | |
Gautam et al. | N-Methylpyridinium tosylate catalyzed green and efficient synthesis of some novel 2, 4-disubstituted thiazoles and 4-thiazolidinones | |
CN109467564A (zh) | 一种合成2-取代噻唑并[3,2-a]苯并咪唑类化合物的方法 | |
CN104447686A (zh) | 多取代2-吡咯吡啶衍生物及其制备方法 | |
CN110437124B (zh) | 一种吲哚醌衍生物的制备方法 | |
CN110143935A (zh) | 一种2,5-二取代呋喃衍生物的制备方法 | |
CN111253208A (zh) | 一种1-碘代炔烃的制备方法 | |
CN108610304B (zh) | 一种二芳并磺内酰胺类化合物的合成方法 | |
CN106946875B (zh) | 一种c-3位氧取代的咪唑杂环化合物的制备方法 | |
CN102690239B (zh) | 一种1,5-苯并二氮卓类衍生物的合成方法 | |
CN107540678A (zh) | 一种分子内交叉脱氢偶联制备香豆素并杂芳环类化合物及其衍生物的方法 | |
CN108586519A (zh) | 一种有机硅烷或有机锗烷衍生物的制备方法 | |
CN107400105A (zh) | 一种不对称有机催化高效合成光学活性多取代2,3‑二氢呋喃类化合物的方法 | |
Chen et al. | CuI catalyzed domino coupling–cyclization of 2-iodo-phenols and 1-alkynes to the synthesis of 2-substituted benzo [b] furans/furo-pyridines | |
CN104557957A (zh) | 螺-氧化吲哚环氧乙烷衍生物的合成方法 | |
CN103242371A (zh) | 联芳基吡啶环钯氮杂环卡宾化合物及其制备方法和用途 | |
CN113354655B (zh) | 一种双苯并[5,6]螺环缩酮化合物及其制备方法 | |
CN101628904B (zh) | 一种合成2-硝基-3-芳基-2,3,5,7-四氢苯并呋喃-4-酮衍生物的方法 | |
CN111978167B (zh) | 一种多取代环己-2-烯酮的一步合成方法 | |
CN112625020B (zh) | 一种铑催化碳氢键活化反应合成异香豆素衍生物 | |
CN103613529B (zh) | 吡咯类衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |